Via practica 6/2021

Adiposopathic dyslipidaemia

Obesity (adiposity) can lead to pathogenic reactions of adipocytes and adipose tissue (adiposopathy). Adiposopathy leads to abnormal levels of circulating lipids and lipoproteins with the development of atherogenic dyslipidemia – a risk factor for atherosclerosis-related cardiovascular disease. A characteristic feature of dyslipidemia in obesity/diabesity is a cluster of quantitative and qualitative changes in lipid and lipoprotein metabolism, which lead to increased plasma atherogenicity. Focusing on the adiposopathic dyslipidemia complex represents an extension of therapeutic goals. In the management of atherogenic dyslipidaemia, we should use all available options – an ideal combination of non-traditional and traditional management. Selective PPARα modulators are a near future in combination hypolipidemic therapy, and a slightly more distant future will focus on the metabolism of triacylglycerol-rich lipoproteins. These options represent a new opportunity to reduce cardiovascular risk by affecting the adiposopathic/atherogenic dyslipidemia complex.

Keywords: adiposopathic dyslipidemia, traditional management, non-traditional management, the future of pharmacotherapy